Ripretinib
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Ripretinib
Ripretinib: Known uses and market status in Canada
Summary
The TxGNN deep-learning model has no candidate with a score of 0.99 or higher for Ripretinib, so there is currently no new predicted indication. The drug’s recorded uses are listed below. These are its own known uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 1 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| gastrointestinal stromal tumors | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 02500833 | QINLOCK | Valid |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (kinase inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: The interaction screening found 90 potential interactions. Two are Major among those listed: clarithromycin and cobicistat. Most others are Moderate, including:
- Antidiabetic agents: pioglitazone, rosiglitazone, troglitazone, canagliflozin, repaglinide
- Antiemetics: aprepitant, rolapitant
- Azole antifungals: miconazole, clotrimazole
- Others: dexamethasone, cimetidine, eliglustat, fidaxomicin, deferasirox, fostamatinib, selexipag, metreleptin, glycerol phenylbutyrate
- Published pharmacokinetic work suggests that CYP3A4 and P-glycoprotein inhibitors can change ripretinib exposure.
Please refer to the package insert for warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.